Nasal high flow therapy and PtCO₂ in stable COPD: A randomized controlled cross-over trial

STEVEN MCKINSTRY,1,2,3 JANINE PILCHER,1,2,3 GEORGE BARDSLEY,1,3 JAMES BERRY,1 SUSANNE VAN DE HEI,4 IRENE BRAITHWAITE,1,3 JAMES FINGLETON,1,2,3 MARK WEATHERALL3,5 AND RICHARD BEASLEY1,2,3

1Medical Research Institute of New Zealand, Wellington; 2School of Biological Sciences, Victoria University of Wellington, Wellington; 3Capital and Coast District Health Board, Wellington; 4School of Medicine and Health Sciences, University of Otago Wellington, Wellington, New Zealand; 5University of Groningen, Groningen, The Netherlands

ABSTRACT

Background and objective: Hypercapnia is associated with worse clinical outcomes in exacerbations of COPD. The present study aimed to determine the effects of nasal high flow (NHF) therapy on transcutaneous partial pressure of carbon dioxide (PtCO₂) in stable COPD patients.

Methods: In a single-blind randomized controlled cross-over trial, 48 participants with COPD were allocated in random order to all of four 20 min interventions: NHF at 15 L/min, 30 L/min and 45 L/min or breathing room air, with each intervention followed by a washout period of 15 min. The primary outcome measure was PtCO₂ at 20 min, adjusted for baseline PtCO₂. Secondary outcomes included respiratory rate at 20 min, adjusted for baseline. Results: The mean (95% CI) change in PtCO₂ at 20 min was −0.6 mm Hg (−1.1 to 0.0), P = 0.06; −1.3 mm Hg (−1.9 to 0.8), P < 0.001; and −2.4 mm Hg (−2.9 to −1.8), P < 0.001; for NHF at 15 L/min, 30 L/min and 45 L/min compared with room air, respectively. The mean (95% CI) change in respiratory rate at 20 min was −1.5 (−2.7 to −0.3), P = 0.02; −4.1 (−5.3 to −2.9), P < 0.001; and −4.3 (−5.5 to −3.1), P < 0.001; breaths per minute compared with room air, respectively.

Conclusion: NHF results in a small flow-dependent reduction in PtCO₂ and respiratory rate in patients with stable COPD.

Clinical trial registration: ACTRN12615000471583 at anzctr.org.au

Key words: arterial partial pressure, carbon dioxide, chronic obstructive respiratory disease, nasal high flow, randomized controlled trial.

Abbreviations: FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; NHF, nasal high flow; NIV, non-invasive ventilation; PaCO₂, partial pressure of arterial carbon dioxide; PtCO₂, transcutaneous partial pressure of carbon dioxide; RIP, Respiratory Inductance Plethysmography; StO₂, transcutaneous oxygen saturation.

INTRODUCTION

In acute exacerbations of COPD, hypercapnia is associated with worse clinical outcomes including death. Non-invasive ventilation (NIV) is recommended to provide respiratory support to patients with exacerbations of COPD who have hypercapnic respiratory failure despite optimal medical therapy. Tolerability of NIV may be a barrier to effective use and an alternative to NIV is a priority for the management of acute exacerbations of COPD. Nasal high flow (NHF) therapy may cause a modest reduction in the partial pressure of arterial carbon dioxide (PaCO₂) in both stable and acute COPD. However, the interpretation of studies of NHF, and their applicability to clinical practice, remains variably limited by the confounding effect of concomitant oxygen therapy, absence of randomized controlled treatments and a lack of data on the dose–response relationship across the range of flows used in clinical practice.

The present study is a randomized controlled cross-over trial of the effect of three different flow rates of NHF therapy compared with a control intervention of room air, in patients with stable COPD who do not need concomitant oxygen therapy. The main objective of the present study was to determine the flow–response relationship of NHF therapy and PaCO₂ in stable COPD. The hypothesis was that NHF therapy would cause a flow-dependent reduction in PaCO₂ and respiratory rate in stable COPD.

METHODS

In this single-blind, randomized, controlled, four-way cross-over trial, 48 participants with a doctor’s diagnosis of COPD, aged at least 40 years and with a tobacco...
Nasal high flow therapy in stable COPD

smoking history of ≥10 pack years were recruited. Participants were excluded if their forced expiratory volume in 1 s (FEV1)/forced vital capacity ratio was > 0.7, or if they were on long-term oxygen therapy, had a current exacerbation of COPD requiring a short course of antibiotics or oral glucocorticoids or oxygen therapy, or hospitalization for an acute exacerbation of COPD within the last 6 weeks. People with nasal conditions potentially affecting the ability to use NHF were also excluded. Eligible participants attended a single study visit at the MRINZ Respiratory Physiology Laboratory at Wellington Regional Hospital.

The present study was prospectively registered with ANZCTR (Trial ID: ACTRN12615000471583) and approved by the Health and Disability Ethics Committee of New Zealand (Ref: 15/NTA/4). Full written informed consent was completed before any study-specific procedures.

After demographic data was collected, spirometry was performed in accordance with American Thoracic Society/European Respiratory Society criteria using a Jaeger Master screen body volume constant plethysmography unit with pneumotachograph and diffusione unit (Erich-Jaeger, Wurzburg, Germany). Measurements of transcutaneous partial pressure of carbon dioxide (PtCO2), transcutaneous oxygen saturation (SIO2) and heart rate were made using the SenTec transcutaneous monitor (SenTec digital monitor with V-Sign Sensor VS-A/P/N, Therwil, Switzerland; further details in the Appendix S1 in Supplementary Information). The SenTec probe was kept on the patient for between 20 and 30 min before the subsequent study procedures to ensure a stable baseline measurement of PtCO2.

Minute ventilation was measured using Respiratory Inductance Plethysmography (RIP) bands (QDC-Pro device; CareFusion, Yorba Linda, California, USA). Further details are given in the Appendix S1 in Supplementary Information.

Participants received all interventions for 20 min in a randomized order while seated. Each NHF flow setting was at a temperature of 37°C without oxygen: 15 L/min, 30 L/min or 45 L/min; or the control setting of breathing room air only without the NHF attached, using the myAIRVO 2 device (PT101AZ; Fisher and Paykel Healthcare, Auckland, New Zealand). Further details are given in the Appendix S1 in Supplementary Information.

Each of the four interventions was followed by a washout period breathing room air for at least 15 min, allowing the PtCO2 to return to within 4 mm Hg of the baseline measurement for the particular intervention. The washout could be extended until this criterion was met.

PtCO2, StO2, heart rate and respiratory rate were recorded at the start of each intervention and then every 5 min until the end of each washout period.

The order of administration of the four treatments was randomized. The randomisation was computer-generated by the study statistician, who had no role in the recruitment, study visits or data collection. Treatment allocation and maintenance of blinding are described in the Appendix S1 in Supplementary Information.

Participant tolerability questionnaires were administered during the washout periods after each NHF intervention. Participants rated the ease of application, level of comfort, weight of the nasal interface, noisiness, amount of moisture in the nasal passages and likelihood of reusing the system on a continuous scale from most positive (0) to least positive (100).

Outcomes
The primary outcome was PtCO2 at 20 min, adjusted for baseline PtCO2. Secondary outcomes were: the proportion of participants who had a decrease in PtCO2 ≥4 mm Hg from baseline during the intervention; PtCO2, respiratory rate, StO2, heart rate and minute ventilation adjusted for baseline for each 5-min time-point during the intervention and the subsequent 15 min washout period; the proportion of participants who withdrew from the intervention before it was completed; and results of the tolerability questionnaires.

Statistical analysis
The paired SDs of PtCO2 in a previous study investigating oxygen administration to patients with stable COPD were between 1.8 and 4.4 mm Hg. Based on the highest PtCO2 SD of 4.4 mm Hg, and an alpha value of 0.0083 (to take into account the potential for six possible comparisons for the four-way cross-over study) a sample size of 48 had 90% power to detect a difference in PtCO2 of 3.8 mm Hg.

The comparison of each of the three NHF treatments compared to room air was by mixed linear model with fixed effects for the randomisation sequence, the baseline measurement of the particular variable, and the randomized treatment, time and their interaction; and a random effect for each participant, with an exponential time correlation structure for the repeated measurements. The comparison of paired proportions for those that had a decrease from baseline PtCO2 of ≥4 mm Hg was by an exact McNemar’s test and estimation of the CI for the differences in paired proportions, NHF intervention minus room air, by an asymptotic method. The comparison of device questionnaire scores was by a mixed linear model with fixed effects for the randomisation sequence and treatment; and a random effect for the participant. In a post hoc analysis, the statistical test of whether the PtCO2 response to treatment differed by whether the baseline PtCO2 was >45 mm Hg or not was the interaction P value. The above-mentioned analysis was carried out using the SAS (SAS, Cary, NC, USA) version 9.4 package.

RESULTS

Participant characteristics
Contact was made with 84 potentially eligible participants of whom 48 were randomized between May 2015 and February 2016 (Fig. 1).

Three participants required an extended washout in at least one of the interventions past the planned 15 min washout for the PtCO2 to return to within 4 mm
Transcutaneous partial pressure of carbon dioxide

The mean PtCO₂ adjusted for baseline after 20 min compared to room air was lower for NHF with a flow-dependent reduction in PtCO₂ (Table 2). The mean difference in PtCO₂ compared to room air was −2.4 mm Hg (95% CI: −2.9 to −1.8), P < 0.001, −1.3 mm Hg (95% CI: −1.9 to −0.8), P < 0.001 and −0.6 mm Hg (95% CI: −1.1 to 0.0), P = 0.06 for NHF at 45 L/min, 30 L/min and 15 L/min, respectively. There was no significant interaction between treatment response and whether the baseline PtCO₂ was greater than 45 mm Hg or not, P = 0.74.

The proportion of participants with at least one measurement of PtCO₂ which decreased from baseline ≥8 mm Hg, up to and including the 20-min treatment period for NHF at 45 L/min.

Oxygen saturation and heart rate

The StO₂ was higher for NHF 45 L/min compared to room air at the 5, 15 and 20 min time points. The mean maximum difference in StO₂ was 0.8% (95% CI: 0.41–1.28), P < 0.001, observed after 5 min for NHF 45 L/min compared to room air (Table S1 (Supplementary Information)).

Heart rate remained largely constant throughout the interventions with no statistically significant differences between any of the NHF interventions and room air, with the exception of the 20-min time point for the 15 L/min where it was 2 beats per minute higher (95% CI: 0.25–3.8), P = 0.025 (Table S2 (Supplementary Information)).

The full-set of mean data for each variable is shown in the Tables S3–S6 in Supplementary Information.

Minute ventilation

In 97/192 (51%) interventions, the RIP measurements were valid, and of the 144 planned comparisons between NHF and room air, in only 52 (36%) were both NHF and room air measurements valid. For this reason, the RIP data is not presented.

Tolerability questionnaires

Participant feedback was that NHF at 45 L/min was less comfortable and noisier, but moister than NHF at 15 L/min (Table 4). NHF at 30 L/min was generally more tolerable than 45 L/min.

DISCUSSION

The NHF device resulted in a small flow-dependent reduction in the PtCO₂ in participants with stable COPD. There was a marked flow-dependent reduction in respiratory rate with the use of NHF. These findings suggest a favourable physiological effect with NHF in stable COPD.

There are a number of methodological issues relevant to the interpretation of the study findings. Our study was single-blinded in that although participants were blinded to the actual flow rate they received, they could feel the difference between low, medium and high flows. The interventions were applied for 20 min periods, which was sufficient time to observe an effect on PtCO₂ with the maximum change usually observed at the 5-min time point. There was a washout period
which allowed each of the four intervention periods to begin within a similar baseline PtCO2.

The external validity of the findings was limited in the respect that participants with stable COPD were recruited, rather than during a severe exacerbation, in which NHF is more likely to be administered. However, this design enhanced the internal validity, allowing a cross-over design to be utilized with a single study visit, which importantly enabled a stable baseline PtCO2 to be achieved before each intervention. It also avoided the confounding effect of supplemental oxygen use, a potential limiting factor in previous studies of NHF therapy in exacerbations of COPD, in which lower inspired concentrations of oxygen with NHF may have contributed to the reductions in PaCO2 observed.4–6 There was a broad cross-section of severity of COPD, with one in eight having hypercapnia and one in two having an FEV1 < 50% predicted. A post hoc analysis showed no evidence that the change in PtCO2 in response to treatment varied by whether the patient was in chronic hypercapnic respiratory failure.

The transcutaneous SenTec monitor has been validated and used as a surrogate measure of PaCO2, allowing continuous monitoring and the avoidance of multiple arterial blood gas punctures.13–17 The RIP measures were not valid for most interventions and so it was not possible to directly measure the effect of NHF on minute ventilation or tidal volume.

Our observations showed that NHF reduces PtCO2 in a flow-dependent manner complements previous work. The small reduction in PtCO2 of 2.4 mm Hg at 45 L/min is similar to the 3.4 mm Hg reduction with NHF at 30 L/min for 20 min in COPD patients on long-term oxygen therapy,4 the 3.1 mm Hg reduction with NHF at 20 L/min for 45 min in COPD patients requiring supplemental oxygen at 2 L/min in hospital,6 and the reduction of 1.4 mm Hg observed in our previous study of patients hospitalized with exacerbations of COPD, where supplemental oxygen delivered with NHF was titrated to maintain patient StO2 at hospital pre-study levels.7 However, it is less than the 5.2 mm Hg and 7.3 mm Hg reduction in PtCO2 observed with 2 h of NHF treatment, at 20 L/min and 30 L/min respectively, in the uncontrolled trial of hospitalized COPD patients8 and the non-significant 4.0 mm Hg and 5.5 mm Hg reduction in PaCO2 in COPD patients with chronic hypercapnic respiratory failure receiving NHF therapy for 30 min at 20 L/min and 30 L/min, respectively.9 While the mean reduction in PtCO2 of 2.4 mm Hg found in our study is of uncertain clinical

### Table 1 Baseline participant characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean (SD)</th>
<th>Median (IQR)</th>
<th>Min to max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>69.4 (8.6)</td>
<td>70 (62–74)</td>
<td>52–87</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.6 (6.7)</td>
<td>25.7 (53.4–30.3)</td>
<td>14.5–48.4</td>
</tr>
<tr>
<td>FEV1 (L)</td>
<td>1.55 (0.64)</td>
<td>1.44 (1.03–1.87)</td>
<td>0.50–3.0</td>
</tr>
<tr>
<td>FEV1/FVC (%)</td>
<td>47.2 (11.5)</td>
<td>47.5 (36.2–55.1)</td>
<td>28.4–66.9</td>
</tr>
<tr>
<td>FEV1 % predicted</td>
<td>52.5 (19.6)</td>
<td>49.6 (37.2–68.2)</td>
<td>18.5–88.6</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>3.24 (0.88)</td>
<td>3.10 (2.58–3.90)</td>
<td>1.63–5.41</td>
</tr>
<tr>
<td>Smoking pack years</td>
<td>46.1 (31.2)</td>
<td>41.5 (30.0–58.0)</td>
<td>13.0–200.0</td>
</tr>
<tr>
<td>MMRC</td>
<td>1.17 (0.31)</td>
<td>1 (0–2)</td>
<td>0–3</td>
</tr>
<tr>
<td>PtCO2 (mm Hg)</td>
<td>37.8 (6.1)</td>
<td>36.7 (33.8–39.6)</td>
<td>28.8–55.8</td>
</tr>
<tr>
<td>StO2 (%)</td>
<td>94.9 (2.4)</td>
<td>95.0 (94.1–97.0)</td>
<td>88–99</td>
</tr>
<tr>
<td>Respiratory rate (breaths per minute)</td>
<td>17.8 (5.5)</td>
<td>16.5 (14.0–21.5)</td>
<td>7.0–30.0</td>
</tr>
<tr>
<td>Heart rate (beats per minute)</td>
<td>74.6 (14.1)</td>
<td>74.5 (66.6–81.0)</td>
<td>48.0–118</td>
</tr>
</tbody>
</table>

| Gender male                           | 29 (60.4)          |

**Co-morbidities**

- Asthma: 4 (8.3)
- Bronchiectasis: 1 (2.1)
- Heart failure: 3 (6.3)

**Ethnicity**

- European: 32 (66.7)
- Maori: 9 (18.8)
- Other: 6 (12.5)
- Pacific: 1 (2.1)

**Treatment**

- Inhaled corticosteroid: 34 (70.8)
- Long-acting beta-agonist: 34 (70.8)
- Long-acting muscarinic antagonist: 19 (40.0)
- Short-acting beta-agonist: 34 (70.8)
- Short-acting muscarinic antagonist: 15 (31.3)

FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IQR, interquartile range; MMRC, Modified Medical Research Council; PtCO2, transcutaneous carbon dioxide, StO2, transcutaneous oxygen saturation.
Table 2  PtCO₂ values and mixed linear models for difference in PtCO₂ of NHF minus room air adjusted for baseline (time zero)

<table>
<thead>
<tr>
<th>Time point (min)</th>
<th>Air</th>
<th>NHF 15 L/min</th>
<th>NHF 30 L/min</th>
<th>NHF 45 L/min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PtCO₂ (mm Hg) Mean (SD)</td>
<td>PtCO₂ (mm Hg) Mean (SD)</td>
<td>PtCO₂ (mm Hg) Mean (95% CI)</td>
<td>PtCO₂ (mm Hg) Mean (95% CI)</td>
</tr>
<tr>
<td>0</td>
<td>38.4 (5.5)</td>
<td>37.9 (5.5)</td>
<td>38.0 (5.6)</td>
<td>38.2 (5.1)</td>
</tr>
<tr>
<td>5</td>
<td>38.6 (5.3)</td>
<td>37.4 (5.3)</td>
<td>37.0 (5.9)</td>
<td>36.3 (6.0)</td>
</tr>
<tr>
<td>10</td>
<td>38.6 (5.3)</td>
<td>37.6 (5.4)</td>
<td>36.9 (6.1)</td>
<td>36.0 (6.1)</td>
</tr>
<tr>
<td>15</td>
<td>38.7 (5.2)</td>
<td>37.9 (5.3)</td>
<td>37.1 (6.0)</td>
<td>36.4 (5.9)</td>
</tr>
<tr>
<td>20</td>
<td>38.8 (5.0)</td>
<td>38.0 (5.3)</td>
<td>37.3 (6.0)</td>
<td>36.3 (5.6)</td>
</tr>
</tbody>
</table>

NHF, nasal high flow; PtCO₂: transcutaneous partial pressure of carbon dioxide.

Table 3  Mixed linear models for difference in respiratory rate of NHF minus room air adjusted for baseline (time zero)

<table>
<thead>
<tr>
<th>Time points (min)</th>
<th>Air</th>
<th>NHF 15 L/min</th>
<th>NHF 30 L/min</th>
<th>NHF 45 L/min</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR (bpm) Mean (SD)</td>
<td>RR (bpm) Mean (SD)</td>
<td>RR (bpm) Mean (95% CI)</td>
<td>RR (bpm) Mean (95% CI)</td>
</tr>
<tr>
<td>0</td>
<td>18.2 (4.7)</td>
<td>17.6 (4.9)</td>
<td>18.1 (5.7)</td>
<td>18.3 (4.8)</td>
</tr>
<tr>
<td>5</td>
<td>17.9 (4.9)</td>
<td>15.4 (4.9)</td>
<td>13.3 (4.8)</td>
<td>12.9 (5.5)</td>
</tr>
<tr>
<td>10</td>
<td>17.1 (4.6)</td>
<td>15.0 (5.0)</td>
<td>12.6 (4.4)</td>
<td>12.9 (5.7)</td>
</tr>
<tr>
<td>15</td>
<td>17.1 (4.9)</td>
<td>15.9 (5.3)</td>
<td>13.6 (5.2)</td>
<td>12.9 (5.0)</td>
</tr>
<tr>
<td>20</td>
<td>17.5 (4.8)</td>
<td>16.0 (5.7)</td>
<td>13.4 (5.2)</td>
<td>13.3 (4.8)</td>
</tr>
</tbody>
</table>

bpm: breaths per minute; NHF, nasal high flow; RR, respiratory rate
significance, the reduction in PtCO$_2$ from baseline of ≥8 mm Hg in 4/48 participants on NHF at 45 L/min suggests this therapy may have clinically important effects on PtCO$_2$ in a proportion of patients with COPD.

The reduction in respiratory rate with NHF we observed has been reported in healthy volunteers, in COPD patients, and in other clinical situations such as pulmonary fibrosis and post-cardiac surgical patients. The magnitude of the reduction in respiratory rate was marked with a maximum 5 breaths per minute reduction after 5 min of NHF at 45 L/min, representing a >25% reduction in respiratory rate. It has recently been reported that in patients with COPD and chronic hypercapnic respiratory failure that a reduction in respiratory rate of this magnitude with NHF, nasal high flow therapy in stable COPD

<table>
<thead>
<tr>
<th>Question</th>
<th>NHF 30 L/min minus NHF 15 L/min</th>
<th>NHF 45 L/min minus NHF 15 L/min</th>
<th>P overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ease of application</td>
<td>3.7 (0.7 to 6.7)</td>
<td>2.7 (−0.3 to 5.8)</td>
<td>0.046</td>
</tr>
<tr>
<td>Overall comfort</td>
<td>11.0 (4.5 to 17.4)</td>
<td>20.2 (13.8 to 26.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Moisture in nasal passages</td>
<td>−0.02 (−4.3 to 4.2)</td>
<td>−7.7 (−11.9 to −3.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Noisiness</td>
<td>11.6 (4.1 to 19.1)</td>
<td>28.4 (20.9 to 35.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Likelihood of reusing NHF</td>
<td>3.0 (−2.9 to 9.0)</td>
<td>2.5 (−3.4 to 8.5)</td>
<td>0.55</td>
</tr>
<tr>
<td>Weight of nasal cannula</td>
<td>1.5 (−3.5 to 6.4)</td>
<td>3.1 (−1.8 to 8.1)</td>
<td>0.46</td>
</tr>
</tbody>
</table>

NHF, nasal high flow.

REFERENCES

4. Fraser JE, Spooner AI, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces prongs and it was generally well tolerated in our study. Given NHF at 30 L/min reduced PtCO$_2$ and respiratory rate by a similar amount to NHF at 45 L/min, but was more comfortable, this flow rate may be preferred in clinical practice.

In conclusion, NHF results in a small reduction in PtCO$_2$ and a marked reduction in respiratory rate, in a flow-dependent manner with the higher the flow the greater the effect. Further studies need to be undertaken to compare NHF against the gold standard of NIV in acute exacerbations of COPD associated with respiratory failure.

Acknowledgements

The Medical Research Institute of New Zealand is supported by Health Research Council of New Zealand Independent Research Organization Funding. S.M., J.P. and I.B. are Health Research Council of New Zealand Clinical Training Fellows.

Disclosure statement

The study was funded by Fisher and Paykel Healthcare New Zealand. Study design, conduct, data analysis and manuscript write-up were performed by the Medical Research Institute of New Zealand, independently of the funder.


Supplementary Information

Additional supplementary information can be accessed via the html version of this article at the publisher’s website.

Appendix S1 Methods.

Table S1 Mixed linear models for Oxygen saturation difference in NHF minus room air adjusted for baseline (time zero).

Table S2 Mixed linear models for Heart rate difference in NHF minus room air adjusted for baseline (time zero).

Table S3 Data description for transcutaneous carbon dioxide (PtCO2) by intervention and time.

Table S4 Data description for respiratory rate by intervention and time.

Table S5 Data description for heart rate by intervention and time.

Table S6 Data description for transcutaneous oxygen saturation (StO2) by intervention and time.